Antibody data
- Antibody Data
- Antigen structure
- References [9]
- Comments [0]
- Validations
- Immunohistochemistry [2]
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AB-293-NA - Provider product page
- Provider
- R&D Systems
- Product name
- Human VEGF165 Antibody
- Antibody type
- Polyclonal
- Description
- Protein A or G purified. Detects human VEGF165 and human VEGF121 in direct ELISAs and Western blots. In direct ELISAs, less than 10% cross-reactivity with recombinant mouse VEGF and recombinant rat VEGF is observed.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Unconjugated
- Antigen sequence
AAV38412
- Isotype
- IgG
- Vial size
- 1 mg
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Vasculogenic mimicry formation in EBV-associated epithelial malignancies.
High Plasma Lipid Levels Reduce Efficacy of Adenovirus-Mediated Gene Therapy.
Extensive podocyte loss triggers a rapid parietal epithelial cell response.
Differential expression of vascular endothelial growth factor in high- and low-metastasis cell lines of salivary gland adenoid cystic carcinoma.
A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma.
Exogenous recombinant dimeric neuropilin-1 is sufficient to drive angiogenesis.
Vascular endothelial growth factor is up-regulated after status epilepticus and protects against seizure-induced neuronal loss in hippocampus.
Vascular endothelial growth factor (VEGF) expression in oral tissues: possible relevance to angiogenesis, tumour progression and field cancerisation.
Vascular endothelial growth factor (VEGF) expression in oral tissues: possible relevance to angiogenesis, tumour progression and field cancerisation.
Xiang T, Lin YX, Ma W, Zhang HJ, Chen KM, He GP, Zhang X, Xu M, Feng QS, Chen MY, Zeng MS, Zeng YX, Feng L
Nature communications 2018 Nov 27;9(1):5009
Nature communications 2018 Nov 27;9(1):5009
High Plasma Lipid Levels Reduce Efficacy of Adenovirus-Mediated Gene Therapy.
Kivelä AM, Huusko J, Gurzeler E, Laine A, Dijkstra MH, Dragneva G, Andersen CB, Moestrup SK, Ylä-Herttuala S
Scientific reports 2017 Mar 24;7(1):386
Scientific reports 2017 Mar 24;7(1):386
Extensive podocyte loss triggers a rapid parietal epithelial cell response.
Hakroush S, Cebulla A, Schaldecker T, Behr D, Mundel P, Weins A
Journal of the American Society of Nephrology : JASN 2014 May;25(5):927-38
Journal of the American Society of Nephrology : JASN 2014 May;25(5):927-38
Differential expression of vascular endothelial growth factor in high- and low-metastasis cell lines of salivary gland adenoid cystic carcinoma.
Kondo S, Mukudai Y, Soga D, Nishida T, Takigawa M, Shirota T
Anticancer research 2014 Feb;34(2):671-7
Anticancer research 2014 Feb;34(2):671-7
A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma.
Lewin J, Khamly KK, Young RJ, Mitchell C, Hicks RJ, Toner GC, Ngan SY, Chander S, Powell GJ, Herschtal A, Te Marvelde L, Desai J, Choong PF, Stacker SA, Achen MG, Ferris N, Fox S, Slavin J, Thomas DM
British journal of cancer 2014 Dec 9;111(12):2254-61
British journal of cancer 2014 Dec 9;111(12):2254-61
Exogenous recombinant dimeric neuropilin-1 is sufficient to drive angiogenesis.
Uniewicz KA, Cross MJ, Fernig DG
The Journal of biological chemistry 2011 Jan 7;286(1):12-23
The Journal of biological chemistry 2011 Jan 7;286(1):12-23
Vascular endothelial growth factor is up-regulated after status epilepticus and protects against seizure-induced neuronal loss in hippocampus.
Nicoletti JN, Shah SK, McCloskey DP, Goodman JH, Elkady A, Atassi H, Hylton D, Rudge JS, Scharfman HE, Croll SD
Neuroscience 2008 Jan 2;151(1):232-41
Neuroscience 2008 Jan 2;151(1):232-41
Vascular endothelial growth factor (VEGF) expression in oral tissues: possible relevance to angiogenesis, tumour progression and field cancerisation.
Carlile J, Harada K, Baillie R, Macluskey M, Chisholm DM, Ogden GR, Schor SL, Schor AM
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2001 Sep;30(8):449-57
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2001 Sep;30(8):449-57
Vascular endothelial growth factor (VEGF) expression in oral tissues: possible relevance to angiogenesis, tumour progression and field cancerisation.
Carlile J, Harada K, Baillie R, Macluskey M, Chisholm DM, Ogden GR, Schor SL, Schor AM
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2001 Sep;30(8):449-57
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2001 Sep;30(8):449-57
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- VEGF in Human Breast Cancer Tissue. VEGF was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using Human VEGF 165 Polyclonal Antibody (Catalog # AB-293-NA) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Lower panel shows a lack of labeling if primary antibodies are omitted and tissue is stained only with secondary antibody followed by incubation with detection reagents. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- VEGF165 in Human Breast Cancer Tissue. VEGF165 was detected in immersion fixed frozen sections of human breast cancer tissue using 5 µg/mL Human VEGF165 Polyclonal Antibody (Catalog # AB-293-NA) overnight at 4 °C. Tissue was stained (red) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections.
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Cell Proliferation Induced by VEGF165 and Neutralization by Human VEGF Antibody. Recombinant Human VEGF165 (Catalog # 293-VE) stimulates proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human VEGF165 (10 ng/mL) is neutralized (green line) by increasing concentrations of Human VEGF 165 Polyclonal Antibody (Catalog # AB-293-NA). The ND50 is typically 0.6-3.0 µg/mL.